Refractory PCME is a rare, but serious vision-threatened complication of cataract surgery. For this reason, this complication has to be managed timely and adequate. Non-steroidal and steroidal anti-inflammatory and anti-VEGF agents like bevacizumab are useful for refractory PCME. OCT has an important role in detecting PCME and measuring central macular thickness to control the treatment of PCME. In this case study, a patient is described after routine uncomplicated PACO surgery with refractory PCME at postop 4th week. Despite using topical NSAID+steroidal anti-inflammatory treatment there was no improvement in poor vision and CMT remained stable increased (811 μm). The vision was increased only after 2 weeks of i.v. bevacizumab injection, macular edema resolved and CMT decreased (280 μm) which was revealed by OCT. In conclusion, OCT-guided i.v. bevacizumab is a safe and well-tolerated therapeutic option for refractory PCME.